Delving into the Latest Updates on Recombinant humanized anti-Muc1 antibody conjugated to Tub201(Hangzhou DAC Biotechnology) with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

Target

MUC1

Mechanism

MUC1 inhibitors(Mucin-1 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Advanced Malignant Solid NeoplasmColorectal CancerPancreatic Cancer

Inactive Indication-

Originator Organization

Hangzhou DAC Biotechnology Co., Ltd.

Active Organization

Hangzhou DAC Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

评价DXC005在晚期实体瘤患者中的安全性和耐受性，确定DXC005的最大耐受剂量（MTD）和剂量限制性毒性（DLT），确定Ⅱ期临床试验推荐剂量（RP2D）。评价DXC005在晚期实体瘤患者体内的药代动力学（PK）特征。评价DXC005在晚期实体瘤患者体内产生的免疫原性、抗肿瘤活性。探讨患者肿瘤组织中靶点表达与治疗效果的相关性。探讨患者血液中肿瘤标志物CA242与治疗效果的相关性。

[Translation]

Evaluate the safety and tolerability of DXC005 in patients with advanced solid tumors, determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of DXC005, and determine the recommended dose (RP2D) for Phase II clinical trials. Evaluate the pharmacokinetic (PK) characteristics of DXC005 in patients with advanced solid tumors. Evaluate the immunogenicity and anti-tumor activity of DXC005 in patients with advanced solid tumors. Explore the correlation between target expression in patient tumor tissues and treatment efficacy. Explore the correlation between tumor marker CA242 in patient blood and treatment efficacy.

Start Date05 Jul 2022

Sponsor / Collaborator

Hangzhou DAC Biotechnology Co., Ltd.

100 Clinical Results associated with Recombinant humanized anti-Muc1 antibody conjugated to Tub201(Hangzhou DAC Biotechnology)

Login to view more data

100 Translational Medicine associated with Recombinant humanized anti-Muc1 antibody conjugated to Tub201(Hangzhou DAC Biotechnology)

Login to view more data

100 Patents (Medical) associated with Recombinant humanized anti-Muc1 antibody conjugated to Tub201(Hangzhou DAC Biotechnology)

Login to view more data

100 Deals associated with Recombinant humanized anti-Muc1 antibody conjugated to Tub201(Hangzhou DAC Biotechnology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	CN	Hangzhou DAC Biotechnology Co., Ltd.	05 Jul 2022
Colorectal Cancer	Phase 1	CN	Hangzhou DAC Biotechnology Co., Ltd.	02 Jun 2022
Pancreatic Cancer	Phase 1	CN	Hangzhou DAC Biotechnology Co., Ltd.	02 Jun 2022